Commercial real estate platform biproxi announced that it has acquired OfficeSpace.com, a commercial real estate (CRE) data and listing website.
biproxi plans to consolidate all of its commercial real estate (CRE) data and listings on the OfficeSpace.com. ”With the OfficeSpace.com acquisition, the company will no longer list properties on its biproxi.com website,” said in a statement.
”OfficeSpace.com is already the second-largest commercial real estate(CRE) listing website in the U.S. with over 550,000 listings, and is visited by over 350,000 buyers and tenants every month. It has historical data on over 1.7 million listings reaching back over 15 years,” added biproxi.
READ ALSO : CoStar Group to acquire RentPath for $588m
“We’re excited to add OfficeSpace.com to the suite of products and services available from biproxi and to expand their offerings more broadly to the commercial real estate community,” said biproxi CEO Gordon Smith. “This acquisition will allow us to aggressively build on the success that OfficeSpace.com has seen as a listing site, while also continuing to develop a robust set of solutions for brokers under the biproxi brand.”
“OfficeSpace.com customers can rest assured that biproxi will maintain the current user experience on the site,” Smith noted. “But we also plan to add a broker dashboard and a listing management tool, along with tenant/buyer search capabilities for investment sales and off-market properties to work in concert with the other solutions that the company offers today. We’re bringing the best of both worlds together into one robust offering buyers and brokers alike will love.”
“We are excited that biproxi will continue building on OfficeSpace.com’s success. We looked at several alternatives, and based on the stellar track record of biproxi’s management team and the complementary fit of our business models, it is difficult to imagine a better strategic outcome,” said Susie Algard, Founder and former CEO of OfficeSpace.com.
As part of the transaction, Algard will also be joining biproxi’s Advisory Board.